NEHA B SAVALIA

Allopathic & Osteopathic Physicians|Internal Medicine YORBA LINDA, CA NPI 1114913043

General Payments — all program years on this page

$2,600.12

  • Category: General Payments
  • Program years: PY2018–2024
  • Record count: 127
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $432.54 across 20 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

Nature of paymentAmountRecords
Food and Beverage $432.5420

By paying entity

Latest program year (PY2024) · sorted by reported total.

Paying entityAmountRecords
PFIZER INC. $108.485
Lilly USA, LLC $93.395
Novo Nordisk AS $85.043
Boehringer Ingelheim Pharmaceuticals, Inc. $68.654
Amgen Inc. $57.572
GlaxoSmithKline, LLC. $19.411

By program year

Program yearAmountRecords
2018 $639.9836
2019 $687.7333
2020 $101.725
2021 $22.011
2022 $174.669
2023 $541.4823
2024 $432.5420

Records — PY2024 (20)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1096616972 Novo Nordisk Inc $17.53 02/15/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1097464936 Novo Nordisk Inc $18.75 04/25/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1097627301 Novo Nordisk Inc $48.76 04/20/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1116214742 GlaxoSmithKline, LLC. $19.41 04/04/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1117676167 Amgen Inc. $28.95 01/17/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1117676169 Amgen Inc. $28.62 02/03/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1117878949 Boehringer Ingelheim Pharmaceuticals, Inc. $14.44 09/05/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1117878951 Boehringer Ingelheim Pharmaceuticals, Inc. $17.02 08/21/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1117878953 Boehringer Ingelheim Pharmaceuticals, Inc. $17.07 06/06/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1117878955 Boehringer Ingelheim Pharmaceuticals, Inc. $20.12 10/23/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1131118630 PFIZER INC. $29.93 12/05/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1131313508 PFIZER INC. $21.65 04/04/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1131646697 PFIZER INC. $17.64 06/20/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1131666970 PFIZER INC. $18.48 06/27/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1132039238 PFIZER INC. $20.78 09/26/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1135240851 Lilly USA, LLC $23.36 05/30/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1135244712 Lilly USA, LLC $20.58 03/27/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1135244715 Lilly USA, LLC $21.99 02/08/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1135276858 Lilly USA, LLC $13.64 08/01/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1135290865 Lilly USA, LLC $13.82 01/31/2024 Food and Beverage Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.